<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="709">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108922</url>
  </required_header>
  <id_info>
    <org_study_id>18369</org_study_id>
    <secondary_id>I5T-MC-AACN</secondary_id>
    <nct_id>NCT05108922</nct_id>
  </id_info>
  <brief_title>A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)</brief_title>
  <official_title>A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare donanemab to aducanumab on amyloid plaque&#xD;
      clearance in participants with early symptomatic Alzheimer's Disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2021</start_date>
  <completion_date type="Anticipated">July 2, 2024</completion_date>
  <primary_completion_date type="Actual">September 9, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>6 Months</time_frame>
    <description>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Intermediate Subpopulation (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>6 Months</time_frame>
    <description>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the intermediate subpopulation (Superiority) on donanemab versus aducanumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>Baseline, 6 Months</time_frame>
    <description>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>Baseline, 18 Months</time_frame>
    <description>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Noninferiority) on donanemab 6 months versus aducanumab 12 months</measure>
    <time_frame>Baseline, 6 Months, 12 Months</time_frame>
    <description>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Noninferiority) on donanemab 6 months versus aducanumab 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Noninferiority) donanemab 6 months versus aducanumab 18 months</measure>
    <time_frame>Baseline, 6 Months, 18 Months</time_frame>
    <description>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Noninferiority) donanemab 6 months versus aducanumab 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Complete Amyloid Plaque Clearance on donanemab versus aducanumab</measure>
    <time_frame>Baseline to 18 Months</time_frame>
    <description>Time to reach complete amyloid plaque clearance on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) donanemab versus aducanumab</measure>
    <time_frame>Baseline, 6 Months</time_frame>
    <description>Mean Percent Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Mean Percent Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>Baseline, 18 Months</time_frame>
    <description>Mean Percent Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>12 Months</time_frame>
    <description>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>18 Months</time_frame>
    <description>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>12 Months</time_frame>
    <description>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>18 Months</time_frame>
    <description>Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>Baseline, 6 Months</time_frame>
    <description>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</measure>
    <time_frame>Baseline, 18 Months</time_frame>
    <description>Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Brain Amyloid Plaque Reduction on Florbetapir F18 PET Scan (Superiority) donanemab 6 months versus aducanumab 12 months</measure>
    <time_frame>Baseline, 6 Months, 12 Months</time_frame>
    <description>Change from Baseline in Brain Amyloid Plaque Reduction on Florbetapir F18 PET Scan (Superiority) donanemab 6 months versus aducanumab 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Donanemab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donanemab is administered intravenously (IV) every 4 weeks (Q4W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aducanumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aducanumab administered IV per label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donanemab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Donanemab</arm_group_label>
    <other_name>LY3002813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aducanumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Aducanumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gradual and progressive change in memory function reported by the participant or&#xD;
             informant for ≥6 months.&#xD;
&#xD;
          -  Meet florbetapir F18 PET scan criteria.&#xD;
&#xD;
          -  A Clinical Dementia Rating (CDR)-Global Score of 0.5 or 1.&#xD;
&#xD;
          -  Must consent to apolipoprotein E (ApoE) genotyping&#xD;
&#xD;
          -  Must have a mini mental state examination (MMSE) score between 20 and 30&#xD;
&#xD;
          -  Have a study partner who will provide written informed consent to participate, is in&#xD;
             frequent contact with the participant (defined as at least 10 hours per week), and&#xD;
             will accompany the participant to study visits or be available by telephone at&#xD;
             designated times.&#xD;
&#xD;
          -  Have adequate literacy, vision, and hearing for neuropsychological testing in the&#xD;
             opinion of the investigator at the time of screening.&#xD;
&#xD;
          -  Women not of childbearing potential may participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant neurological disease affecting the central nervous system (other than AD),&#xD;
             that may affect cognition or ability to complete the study, including but not limited&#xD;
             to, other dementias, serious infection of the brain, Parkinson's disease, multiple&#xD;
             concussions, history of transient ischemic attack or stroke, or epilepsy or recurrent&#xD;
             seizures (except febrile childhood seizures).&#xD;
&#xD;
          -  Current serious or unstable medical illnesses including cardiovascular, hepatic,&#xD;
             renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively&#xD;
             suicidal or deemed at risk of suicide, or current alcohol or substance abuse),&#xD;
             immunologic, infectious, or hematologic disease and other conditions that, in the&#xD;
             investigator's opinion, could interfere with the analyses in this study; or has a life&#xD;
             expectancy of approximately&#xD;
&#xD;
             ≤24 months.&#xD;
&#xD;
          -  History of clinically significant multiple or severe drug allergies, or severe&#xD;
             posttreatment hypersensitivity reactions (including but not limited to erythema&#xD;
             multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis,&#xD;
             and/or exfoliative dermatitis).&#xD;
&#xD;
          -  History of bleeding disorder or use of medications with platelet anti-aggregant or&#xD;
             anti-coagulant properties (unless aspirin at ≤325 milligram (mg).&#xD;
&#xD;
          -  Have had prior or current treatment with donanemab or aducanumab&#xD;
&#xD;
          -  Have known allergies to donanemab or aducanumab, related compounds, or any components&#xD;
             of the formulation&#xD;
&#xD;
          -  Prior or current participation in any immunotherapy study targeting Amyloid beta&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-2559) or 1-317-615-4559 Mon - Fri 9 am - 5 pm Eastern time (UTC/GMT) - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurology Center of North Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Clinical Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charter Research - Lady Lake</name>
      <address>
        <city>Lady Lake</city>
        <state>Florida</state>
        <zip>32159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinCloud - Maitland</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinCloud - Viera</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merritt Island Medical Research, LLC</name>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimus U Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brainstorm Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conquest Research</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Memory Center, PC</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephson Wallack Munshower Neurology, PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donald S. Marks M.D., P.C.</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adams Clinical</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Professionals</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Medical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of New Jersey</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute of New Jersey</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Diagnostics, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates, Ltd.</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center, LLC</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerwin Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research, Inc</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/7lW96VnHH5irho2IpKQCFM</url>
    <description>A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)</description>
  </link>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment due to Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

